and the European Board for Accreditation in Cardiology (EBAC) to provide continuing medical education for physicians.
H eart failure is a complex and prevalent clinical syndrome that afflicts 6.2 million people in the United States alone (1) . Heart failure is projected to increase to >8 million Americans by 2030 due in part to the aging of the population. Because advanced age is a major risk factor in the development of heart failure, there is a need to identify the age-related mechanisms that contribute to this pathology and investigate whether these new targets can be leveraged in the development of novel therapies.
Although much of the past research on the mechanisms that contribute to heart failure has focused on cardiomyocyte, fibroblast, and endothelial cell biology, it is increasingly recognized that immune cells and their production of cytokines have critical roles in the pathogenesis of this disease (2) .
Accumulating evidence shows that inflammatory cytokines can promote heart failure phenotypes. It has been well established that elevations in interleukin (IL)-1b and tumor necrosis factor (TNF)-a can promote progressive left ventricular dysfunction and remodeling in experimental models (3) (4) (5) . In the patient population, levels of IL-1b and TNFa increase as heart failure worsens, and C-reactive protein levels correlate with impaired exercise capacity and predict death (6) (7) (8) . Collectively, these observations suggest that immune cell infiltration and the overactivation of cytokine signaling can promote heart failure progression (9) .
Clonal hematopoiesis is a condition that is associated with the acquisition of mutations in hematopoietic stem and progenitor cells (HSPCs) that can lead to clonal populations of leukocytes in the blood that exhibit altered immune properties (10, 11) .
Although these clonal expansions in the blood have been known for decades, only recently has it been appreciated that they are associated with increases in all-cause mortality, coronary heart disease, stroke, and heart failure prognosis. Here we review the epidemiological and experimental studies that suggest that clonal hematopoiesis represents a new causal risk factor for cardiovascular disease and discuss how this could impact our view of how to treat patients with heart failure and other cardiovascular conditions.
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ANTI-INFLAMMATORY STRATEGIES IN THE TREATMENT OF HEART FAILURE
Evidence for the involvement of inflammation has led to an interest in evaluating antiinflammatory therapies for the treatment of patients with heart failure (12, 13) . For example, several small randomized trials and short-term studies have evaluated small molecules that inhibit TNF-a for their efficacy in treating heart failure, and encouraging data have been reported (14) (15) (16) . In a small placebo-controlled study evaluating TNF-a antagonism with the soluble TNF receptor etanercept, improvements were found in left ventricular ejection fraction and remodeling, and there was a trend toward improved patient functional status (17) .
However, a subsequent large randomized trial failed to show an effect of etanercept on clinical status, hospitalization, or death in patients with chronic heart failure (18) . Similarly, the treatment of patients with heart failure with infliximab, a monoclonal antibody to TNF-a, did not improve clinical conditions, and high doses of this agent were associated with adverse events (19) . These results may be explained by the complex effects of TNF-a on the heart, as it has been described to exert cardioprotective actions that counterbalance its detrimental effects on the heart (20) .
There has also been interest in targeting the inflammatory cytokine IL-1b in clinical heart failure.
In pilot studies of patients with ST-segment elevation myocardial infarction, the recombinant IL-1 receptor agonist anakinra was shown to have a favorable safety profile and to diminish the inflammatory response and heart failure incidence in these patients (21) (22) (23) . Small proof-of-concept studies in patients with systolic heart failure showed that anakinra improved exercise capacity and quality of life (24) (25) (26) . More recently, escalating doses of the neutralizing IL-1b antibody canakinumab were evaluated in the large placebo-controlled CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) trial for outcomes in patients with a previous myocardial infarction and sustained levels of high-sensitivity C-reactive protein (hsCRP) (27) . Canakinumab therapy led to reductions in the primary composite outcome of myocardial infarction, stroke, or cardiovascular death at the higher doses (28) . Subsequent analysis revealed that the treated cohort could be subgrouped into responders and nonresponders to the therapy. Patients who achieved lower concentrations of hsCRP (to <2 mg/l) after initiating canakinumab responded better to IL-1b inhibition in terms of cardiovascular benefits, whereas no significant benefit was observed among those with hsCRP concentrations at 2 mg/l or above (29) . A similar relationship was observed with reductions in interleukin (IL)-6 levels in response to canakinumab and cardiovascular event reduction (30) .
The CANTOS cohort was composed of patients with a history of heart failure (22%), and subsequent analyses revealed that therapy with canakinumab led to a dose-dependent reduction in heart failure hospitalization and the composite of hospitalization for heart failure or heart failure-related mortality (31) . Similar to the results of the original study, patients who achieved reductions in hsCRP concentrations to <2 mg/l also displayed reductions in the heart failure outcomes, whereas those at 2 mg/l or above did not.
Within the CANTOS trial cohort, an independent single center sub-study found that patients with heart failure treated with canakinumab had significant improvements in peak oxygen consumption at 3 months and in left ventricular ejection fraction at 12 months of therapy (32) .
Collectively, these studies indicate a complex interplay between inflammation and heart failure.
Thus, a deeper understanding of the complexities of the immune system may be useful for the development of effective anti-inflammatory therapies for heart failure.
AGE-RELATED CLONAL HEMATOPOIESIS
Previous human genetic research in cardiovascular disease has largely focused on the risk caused by germline variations in DNA. However, recent evidence shows that there is a surprisingly high degree of mosaicism in the human body that results from the time-dependent acquisition of somatic mutations that lead to cell-to-cell genomic differences (33) . Ge- 
HSPCs typically reside in the bone marrow, give rise to multiple cell types in the blood, and regenerate via a self-renewal process (35) . Human HSPCs acquire random somatic mutations over time (36) .
Although most of these mutations will have little or no effect on cellular fitness, some provide HSPCs with a competitive advantage within the bone marrow niche that can be detected as a clonal expansion in the blood and other tissues infiltrated by blood cells. These clonal expansions can occur in healthy individuals who lack overt signs of hematologic disorders, and they become prevalent with age ( Figure 1A ). This condition has been historically referred to as clonal hematopoiesis (the terminology that will be used here) and more recently as clonal hematopoiesis of indeterminate potential (37) and age-related clonal hematopoiesis (38) It has long been appreciated that clonal hematopoiesis occurs in elderly individuals who lack a detectable hematologic disorder. Early work was based on studies analyzing the ratio of maternal to paternal X chromosome inactivation in leukocytes.
For example, a study of X chromosome inactivation skewing in 1996 reported clonal expansions in 38% of healthy women over the age of 60 years, but this condition was rarely detected in young women (42) .
Subsequently, it was reported that X chromosome inactivation skewing is associated with mutations in the epigenetic regulator ten-eleven translocation-2 (TET2), a blood cancer "driver gene" (43) . In 2014, 3 independent studies used exome sequencing of peripheral blood to document the widespread occurrence of clonal hematopoiesis in various cohorts (39, 40, 44) . These studies largely focused on clonal Yura et al.
initially reported that individuals with clonal hematopoiesis had significantly increases in the risks of incident coronary heart disease and ischemic stroke after adjusting for age and traditional risk factors.
This increased risk was notable when the variant allele fraction (VAF) of the mutation within the leukocyte pool was 0.10 or greater. In this analysis, the risk of coronary heart disease and ischemic stroke was higher in carriers of clonal hematopoiesis than for individuals with traditional risk factors such as hypertension and high body mass index. Because this was an unplanned secondary analysis, Jaiswal et al. Yura et al. Hematopoietic stem and progenitor cells (HSPCs) acquire random somatic mutations over time. Occasionally, these mutations occur in driver genes (yellow circles)
that provide the HSPC with a competitive advantage, and this leads to clonal expansion in a limiting bone marrow niche. This process is referred to as clonal hematopoiesis, and it can be prevalent in individuals who lack overt signs of hematologic disorders. These mutant HSPCs give rise to progeny immune cells that harbor the mutant gene. This condition may alter the phenotype of the leukocyte and contribute to heart failure. Our recent study assessed the impact of HSPC Dnmt3a mutations on experimental heart failure (68).
In this study, Dnmt3a deficiency in lineage-negative In this regard, it is possible that some clonal hematopoiesis driver genes will be highly pathological, whereas others will be relatively benign with E-mail: kw9ar@virginia.edu.
